PDF DatasheetHuman Anti-Thymidylate Synthase Antibody Product Attributes
Thymidylate Synthase Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Thymidylate Synthase antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in hematopoietic cells in the bone marrow and germinal center cells in the lymph node and tonsil. More moderate antibody staining intensity was present in hematopoietic cells in the bone marrow and germinal center cells in the lymph node and tonsil. Low, but measureable presence of Thymidylate Synthase could be seen inglandular cells in the breast, myoepithelial cells in the breast, respiratory epithelial cells in the bronchus, endothelial cells in the cerebral cortex, neuropil in cerebral cortex, glandular cells in the cervix, uterine, endothelial cells in the colon, glandular cells in the endometrium, squamous epithelial cells in the esophagus, glandular cells in the fallopian tube, myocytes in heart muscle, cells in the glomeruli in kidney, cells in the tubules in kidney, bile duct cells in the liver, hepatocytes in liver, ovarian stroma cells in the ovary, glandular cells in the prostate, myocytes in skeletal muscle, fibroblasts in skin, Langerhans in skin, melanocytes in skin, smooth muscle cells in the smooth muscle, fibroblasts in mesenchymal tissue, cells in the red pulp in spleen, cells in the white pulp in spleen and glandular cells in the thyroid gland. We were unable to detect Thymidylate Synthase in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Thymidylate Synthase expression as measured by anti-Thymidylate Synthase antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ |
| TYMS Variability | ++ | ++ | ++ | + | + | ++ | ++ | + | ++ | ++ | + | ++ | + | + | ++ | ++ | ++ | ++ | + | + |
| Thymidylate Synthase General Information | |
|---|---|
| Alternate Names | |
| Thymidylate synthetase, TYMS | |
| Molecular Weight | |
| 36kDa | |
| Chromosomal Location | |
| 18p11.32 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | TYMS |
| Entrez Gene ID | 7298 |
| Ensemble Gene ID | ENSG00000176890 |
| RefSeq Protein Accession(s) | NP_001341797, NP_001062, NP_001341796 |
| RefSeq mRNA Accession(s) | NM_001354868 NM_001071, NM_001354867 |
| RefSeq Genomic Accession(s) | NG_028255, NC_000018, NC_018929, |
| UniProt ID(s) | Q53Y97, P04818 |
| UniGene ID(s) | Q53Y97, P04818 |
| HGNC ID(s) | 12441 |
| Cosmic ID(s) | TYMS |
| KEGG Gene ID(s) | hsa:7298 |
| PharmGKB ID(s) | PA359 |
| General Description of Thymidylate Synthase. | |
| It recognizes a protein of 36kDa, identified as Thymidylate Synthase (TS) (EC 2.1.1.45). TS converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. TS is also a critical target for the fluoropyrimidines, an important group of antineoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU, fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates TS by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of TS protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head, neck,, breast carcinomas. | |
There are no reviews yet.